Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2023-02-06 00:00:00 ET · period of report 2023-02-02 · accession 0001104659-23-011255 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-06 | 2023-02-02+ | SUPN | Khattar Jack A. | Pres, CEO, Dir | M - OptEx | $9.56 | +22.8K | 804.5K | +3% | +$218.4K |
| DM | 2023-02-06 | 2023-02-02+ | SUPN | Khattar Jack A. | Pres, CEO, Dir | S - Sale+OE | $42.06 | -13.3K | 804.1K | -2% | -$560.7K |
| DM | 2023-02-06 | 2023-02-02+ | SUPN | Khattar Jack A. | Pres, CEO, Dir | M - OptEx | $0.00 | -22.8K | 25.0K | -48% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-02 | M | A | 22,515 | $9.56 | 817,674 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-03 | M | A | 330 | $9.56 | 804,472 | D | — | — | |
| 3 | Common | Common Stock | 2023-02-03 | S | A | 200 | $42.02 | 804,272 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.01 to $42.03, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| 4 | Common | Common Stock | 2023-02-02 | S | D | 13,532 | $42.06 | 804,142 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.09, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| 5 | Derivative | Employee Stock Option (Right to Buy) | 2023-02-02 | M | D | 22,515 | $0.00 | 25,367 | D | $9.56 · — to 2024-01-23 | 22,515 Common Stock | (F4) The options vested in four equal annual installments beginning on January 23, 2015. |
| 6 | Derivative | Employee Stock Option (Right to Buy) | 2023-02-03 | M | D | 330 | $0.00 | 25,037 | D | $9.56 · — to 2024-01-23 | 330 Common Stock | (F4) The options vested in four equal annual installments beginning on January 23, 2015. |